- Home
- AIM vs SYNX Comparison
AIM vs SYNX Comparison
Compare AIM & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- SYNX
- Stock Information
- Founded
- AIM 1966
- SYNX 2005
- Country
- AIM United States
- SYNX Israel
- Employees
- AIM N/A
- SYNX N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- SYNX
- Sector
- AIM Health Care
- SYNX
- Exchange
- AIM Nasdaq
- SYNX Nasdaq
- Market Cap
- AIM 15.9M
- SYNX 15.6M
- IPO Year
- AIM N/A
- SYNX 2024
- Fundamental
- Price
- AIM $0.22
- SYNX $2.61
- Analyst Decision
- AIM Strong Buy
- SYNX
- Analyst Count
- AIM 2
- SYNX 0
- Target Price
- AIM $3.00
- SYNX N/A
- AVG Volume (30 Days)
- AIM 295.4K
- SYNX 7.9K
- Earning Date
- AIM 11-15-2024
- SYNX 11-26-2024
- Dividend Yield
- AIM N/A
- SYNX N/A
- EPS Growth
- AIM N/A
- SYNX N/A
- EPS
- AIM N/A
- SYNX N/A
- Revenue
- AIM $190,000.00
- SYNX $9,893,000.00
- Revenue This Year
- AIM N/A
- SYNX $52.34
- Revenue Next Year
- AIM $1,086.80
- SYNX N/A
- P/E Ratio
- AIM N/A
- SYNX N/A
- Revenue Growth
- AIM N/A
- SYNX 18.05
- 52 Week Low
- AIM $0.21
- SYNX $2.10
- 52 Week High
- AIM $0.62
- SYNX $4.10
- Technical
- Relative Strength Index (RSI)
- AIM 35.93
- SYNX 36.82
- Support Level
- AIM $0.24
- SYNX $2.50
- Resistance Level
- AIM $0.27
- SYNX $2.94
- Average True Range (ATR)
- AIM 0.02
- SYNX 0.25
- MACD
- AIM -0.00
- SYNX -0.01
- Stochastic Oscillator
- AIM 7.49
- SYNX 33.90
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.